Episode Details

This episode is brought to you by Semafor Healthcare.

Delivered weekly from David Lim, Semafor Healthcare connects the dots between decisions in government, business, and technology to reveal how they impact the future of healthcare. Each edition will provide the analysis you need to understand and stay ahead of a rapidly changing landscape. Subscribe for free.

It's Infrastructure Week and H.R. 3, a far-reaching piece of legislation which contains a series of drug-pricing reforms, is back.

At the end of 2019, the House of Representatives passed H.R. 3 but partisan disagreements prevented the bill from becoming law. Now, elements of H.R. 3 are back on the table as the Biden administration prepares its $2 trillion infrastructure and jobs package.

Washington University's Rachel Sachs joins Health Affairs' Chris Fleming to break down H.R. 3's three main parts and highlight what they mean for the federal budget, pharmaceutical companies, and consumers.

Related Links:

• Prescription Drug Legislation In Congress: An Update (Health Affairs Blog)
• Rachel Sachs' Health Affairs Articles
• Prescription Drug Policy: The Year In Review, And The Year Ahead (Health Affairs Blog)
• Administration Finalizes Most-Favored Nation Drug Pricing Rules At The Last Minute (Health Affairs Blog)
• Democrats Gear Up For Major Push To Lower Drug Prices (The Hill)

Subscribe: RSS | Apple Podcasts | Spotify | Castro | Stitcher | Deezer | Overcast

Subscribe to Semafor Healthcare for free.